Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Unknown 5Recruiting 3Terminated 2Completed 2Active not recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Carcinoma, Non-Small-Cell Lung 33Breast Neoplasms 21Prostatic Neoplasms 17Stomach Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Lung Neoplasms 10Neoplasms 7Neoplasm Metastasis 6Carcinoma, Transitional Cell 5Triple Negative Breast Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Salivary Gland Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Nasopharyngeal Carcinoma 3Melanoma 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Carcinoma 3Recurrence 2Osteosarcoma 2Non-Muscle Invasive Bladder Neoplasms 2Lymphoid Interstitial Pneumonia 2Laryngeal Neoplasms 2HER2-positive Breast Cancer 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2

Interventions

pertuzumab 3Trastuzumab 3Paclitaxel 2Docetaxel 2tucatinib 1trastuzumab deruxtecan 1pegfilgrastim 1atezolizumab 1Carboplatin 1Ado-Trastuzumab Emtansine 1ARX788 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × HER2-positive Breast Cancer × Docetaxel × Clear all
NCT06445400 2026-05-13

A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2 Active not recruiting
83 enrolled
Breast

HER2-positive Breast Cancer

NCT05426486 2024-10-30

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Shengjing Hospital

Phase 2/3 Active not recruiting
136 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡